Physician profile
Robyn Moran
NPI 1609257476
$2,700.62
in general payments reported to CMS, 2019-2025
21 companies · $58.36 in 2025
The $58.36 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $544 · 2022: $873 · 2023: $616 · 2024: $609 · 2025: $58.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,284.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $528.12 | 2021-2024 | |
| Amgen INC. | $457.61 | 2021-2024 | Enbrel, Otezla, Tavneos |
| Pfizer INC. | $256.97 | 2021-2024 | |
| Janssen Biotech, INC. | $220.56 | 2021-2024 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $176.38 | 2021-2024 | Cimzia |
| Sobi, INC | $139.55 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $123.78 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $103.59 | 2022-2024 | Saphnelo, Evusheld |
| Glaxosmithkline, LLC. | $90.46 | 2021-2024 | Benlysta |
| Mallinckrodt Hospital Products INC. | $79.45 | 2021-2024 | Acthar |
| Genentech USA, INC. | $77.32 | 2021-2023 | Actemra, Rituxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.51 | 2022-2023 | Cyltezo |
| Alexion Pharmaceuticals, INC. | $74.26 | 2021-2023 | |
| Organon LLC | $71.33 | 2022-2025 | Renflexis, Hadlima |
| Lilly USA, LLC | $53.92 | 2021-2023 | Taltz |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $47.94 | 2021-2024 | Orencia |
| Teva Pharmaceuticals USA, INC. | $36.87 | 2023-2024 | Truxima |
| Aurinia Pharma U.S., INC. | $32.66 | 2022 | |
| Scilex Pharmaceuticals INC. | $22.43 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $17.12 | 2022 | |
| Hospira, INC. | $14.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.